Skip to main content

Neumora Therapeutics, Inc 10-Q for FY2026 Q3

Neumora Therapeutics, Inc. (NMRA)

10-Q 2026-11-16 For: 2026-09-30
View Original
Added on November 16, 2026

About this 10-Q

Neumora Therapeutics, Inc filed this 10-Q on November 16, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Neumora reported a nine-month net loss of $131.0 million and $85.7 million in cash and cash equivalents as of September 30, 2026, raising substantial doubt about its ability to continue as a going concern within one year of filing. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$34.44M
compared with a net loss of $56.76M a year earlier
Diluted EPS
-$0.18
compared with -$0.35 a year earlier